Enhabit, Inc (EHAB)

Enhabit reported its Q3 2025 earnings, beating EPS estimates but slightly missing revenue expectations, and raised its full-year 2025 revenue guidance. UBS upgraded Enhabit's stock. Enhabit has a consensus recommendation of "Moderate Buy" with an average twelve-month price target of $12.10. Enhabit's stock has increased by 19.7% since January 1, 2026, and has shown positive growth over the last 12 months. Enhabit has consistently reduced its bank debt, resulting in annualized cash interest savings and achieving a leverage ratio of 3.9x.

While specific details are limited, the nature of home health and hospice services suggests potential seasonal fluctuations. Demand might increase during colder months due to higher incidence of respiratory illnesses and decrease during warmer months. Analysts focused on "seasonality in hospice" during a Q3 2025 earnings call.

Enhabit, Inc. is a national provider of home-based healthcare services, operating primarily in the Healthcare sector and the Medical Care Facilities industry. The company delivers personalized clinical and non-clinical services that support patients in their homes, aiding recovery, managing chronic conditions, and providing end-of-life care. Enhabit's service portfolio includes home health services such as skilled nursing, physical therapy, and hospice services like pain management and counseling. Enhabit leverages proprietary care-management technology to streamline clinical workflows and improve care coordination. The company rebranded from Encompass Health Home Health Holdings, Inc. in March 2022.

Enhabit, Inc. has a nationwide footprint across 34 states, with 247 home health locations and 115 hospice locations, operating in both urban and rural markets. In 2023, Enhabit expanded its presence in Florida through the acquisition of Southwest Florida Home Care, increasing its home health locations in that state to 22.

Enhabit's brand reputation is focused on its commitment to quality, compliance, and patient satisfaction in home-based healthcare. The company is pursuing operational efficiencies, new patient admissions growth, and payer contract negotiations. A strategic review concluded with the company continuing as an independent public entity. AREX Capital Management secured board representation through a proxy contest, and the company is undergoing board refreshment.

Enhabit's ownership is primarily distributed among institutional investors and the public. Major institutional shareholders include UBS Group AG, Paradice Investment Management LLC, Deerfield Management Company L.P., 8 Knots Management LLC, BlackRock Advisors LLC, and Vanguard Fiduciary Trust Co. Insiders who own company stock include Ryan Solomon, Jeffrey Bolton, Stuart M. Mcguigan, Ronald Leroy Langham Jr., L. Edward Shaw Jr., Erin Hoeflinger, and Collin Mcquiddy.